Showing 1281-1290 of 3103 results for "".
- Unexpected Association Found Between Certain Beverages and MS Riskhttps://practicalneurology.com/news/unexpected-association-found-between-certain-beverages-and-ms-risk/2470155/A study from Iran published in the Journal of Health, Population and Nutrition found that drinki
- Serum Glial Fibrillary Acidic Protein as Biomarker for MS Progressionhttps://practicalneurology.com/news/serum-glial-fibrillary-acidic-protein-as-biomarker-for-ms-progression/2470110/Serum glial fibrillary acidic protein (sGFAP) concentrations are
- Dimethyl Fumarate Delays MS in Those With Radiologically Isolated Syndromehttps://practicalneurology.com/news/dimethyl-fumarate-delays-ms-in-those-with-radiologically-isolated-syndrome/2470096/Results from the ARISE study (NCT02739542), published in the Annals of Neurology, demonstrated that dimethyl fumarate (Tecfidera; Biogen, Cambridge, MA) delayed the development of multiple scleros
- Phase 3 Trial of New Drug To Treat Progressive MS Approved by FDAhttps://practicalneurology.com/news/phase-3-trial-of-new-drug-to-treat-progressive-ms-cleared-by-fda/2470089/The Food and Drug Administration (FDA) approved a phase 3 clinical trial (NCT05441488) for masitinib (AB Science; Paris, France) as a potential treatment for progressive forms of multiple sclerosi
- Ofatumumab Reduced Annualized Relapse Rate in MS in Phase 3 Clinical Trialshttps://practicalneurology.com/news/ofatumumab-reduced-annualized-relapse-rate-in-ms-in-phase-3-clinical-trials/2469346/As published in The New England Journal of Medicine (NEJM), the ASCLEPIOS 1 (NCT02792218) and 2 (
- DHODH Inhibitor Reduces Lesions Significantly in Relapsing-Remitting MShttps://practicalneurology.com/news/dhodh-inhibitor-reduces-lesions-significantly-in-relapsing-remitting-ms/2469343/A phase 2 clinical trial (NCT03846219) of a selective oral Dihydroorotate dehydrogenase (DHODH) inhibitor (IMU-838; Immunic, New York, NY) provided a significant reduction in lesions in participan
- T-Cell Immunotherapy for Progressive MS Shows Safety and Efficacyhttps://practicalneurology.com/news/t-cell-immunotherapy-for-progressive-ms-shows-safety-and-efficacy/2469276/Data from an ongoing study of an allogeneic EBV T-cell immunotherapy (ATA188; Atara Biotherapeutics, South San Francisco, CA) showed safety and efficacy for the treatment of progressive multiple sclerosis (PMS). Composite scales of clinical outcome and of sustained disability improvement (S
- Data Show Ocrelizumab Reduces Disability Progression and Disease Risk in MShttps://practicalneurology.com/news/data-show-ocrelizumab-reduces-disability-progression-and-disease-risk-in-ms/2469242/Post hoc analysis of data from phase 3 Opera 1 (NCT01247324) and Opera 2 (NCT01298492) studies,
- Alemtuzumab Effective for Treatment of MS Over 8 Years of Follow Uphttps://practicalneurology.com/news/alemtuzumab-effective-for-treatment-of-ms-over-8-years-of-follow-up/2468817/After 8 years of treatment with alemtuzumab (Lemtrada; Sanofi, Bridgewater, NJ), patients treated with 3 or more courses of the drug had an annualized relapse rate (ARR) of 0.18%, 85% of patients have been free of relapses, and 70% of patients had stable or improved scores on the Expanded Disabil
- Jeffrey Cohen, MD, Delivers Kenneth P. Johnson Memorial Lecture at ACTRIMS 2026https://practicalneurology.com/news/jeffrey-cohen-md-delivers-kenneth-p-johnson-memorial-lecture-at-actrims-2026/2485637/The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) has honored Jeffrey Cohen, MD, with the 2026 Kenneth P. Johnson Memorial Lecture, recognizing his longstanding contributions to multiple sclerosis (MS) research, clinical care, and leadership. The annual memorial le